Sandbox Reserved 1107: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
== MraY == | == MraY == | ||
[http://proteopedia.org/wiki/index.php/4j72 MraY], called also '''phospho-N-acetylmuramoyl-pentapeptide-transferase''' or '''UDP-MurNAc-pentapeptide phosphotransferase''', with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.8.13 2.7.8.13], is an integral membrane enzyme involved in peptidoglycan biosynthesis <ref name="one">PMID:29778697</ref> <ref name="two">PMID:27511599</ref>.MraY is encoded by the [https://www.ncbi.nlm.nih.gov/gene/1192662 mraY gene] and belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase (PNPT) superfamily <ref name="three">PMID:23990562</ref>. MRAY is a promising candidate for the development of new antibiotics. In fact, it is the target of five classes of natural nucleoside inhibitors with potent antibacterial activity: the liposidomycins/caprazamycins, capuramycins, mureidomycins, muraymycins, and tunicamycins <ref name="two"/> <ref name="four">PMID:29438582</ref>.The structure presented in this page correspond to the MraY protein from the thermophile [https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=224324 ''Aquifex aeolicus'' strain VF5] | [http://proteopedia.org/wiki/index.php/4j72 MraY], called also '''phospho-N-acetylmuramoyl-pentapeptide-transferase''' or '''UDP-MurNAc-pentapeptide phosphotransferase''', with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.8.13 2.7.8.13], is an integral membrane enzyme involved in peptidoglycan biosynthesis <ref name="one">PMID:29778697</ref> <ref name="two">PMID:27511599</ref>.MraY is encoded by the [https://www.ncbi.nlm.nih.gov/gene/1192662 mraY gene] and belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase (PNPT) superfamily <ref name="three">PMID:23990562</ref>. MRAY is a promising candidate for the development of new antibiotics. In fact, it is the target of five classes of natural nucleoside inhibitors with potent antibacterial activity: the liposidomycins/caprazamycins, capuramycins, mureidomycins, muraymycins, and tunicamycins <ref name="two"/> <ref name="four">PMID:29438582</ref>.The structure presented in this page correspond to the MraY protein from the thermophile [https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=224324 ''Aquifex aeolicus'' strain VF5] (MraYAA) in complex with carbacaprazamycin.MraYAA was expressed in ''Escherichia coli''. | ||
== Carbacaprazamycin == | == Carbacaprazamycin == | ||
<scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>. | <scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>. One particular characteristic of caprazamycin nucleoside inhibitors is that they have uridine on their structure. It has been shown that Mray inhibitors contains a uridine moiety. | ||
== Relevance == | |||
Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY. | Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY. | ||
Revision as of 01:33, 17 January 2020
| ||||||||||||